Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ianalumab versus placebo in previously treated warm autoimmune hemolytic anemia
CTR20230467Phase 3Active
- Sponsor
- Novartis
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ianalumab in warm autoimmune hemolytic anemia (wAIHA), sponsored by Novartis. Started May 2023; status: active.
02
Drugs
ianalumab
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on CTR20230467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230467.